-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-08-02
Values as of: 2024-08-02
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.
Company Website : www.spdrs.com
Currency: USD
Country : USA
Inception Date: 31/01/2006
Primary Benchmark: S&P Biotechnology Select Industry TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.35%
Management Expense Ratio: 0.35 %
N/A
N/A
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. | 0.13 % |
N/A |
USD 42.49B |
| FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
N/A |
USD 3.19B |
| FXH | First Trust Health Care AlphaD.. | 0.63 % |
N/A |
USD 1.30B |
| XHE | SPDR® S&P Health Care Equipme.. | 0.35 % |
N/A |
USD 0.23B |
| IDNA | iShares Genomics Immunology an.. | 0.00 % |
N/A |
USD 0.14B |
| SBIO | ALPS Medical Breakthroughs ETF | 0.50 % |
N/A |
USD 0.11B |
| XHS | SPDR® S&P Health Care Service.. | 0.35 % |
N/A |
USD 0.09B |
| HTEC | Robo Global® Healthcare Techn.. | 0.00 % |
N/A |
USD 0.06B |
| BBP | Virtus LifeSci Biotech Product.. | 0.79 % |
N/A |
USD 0.02B |
| BBC | Virtus LifeSci Biotech Clinica.. | 0.79 % |
N/A |
USD 0.01B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| INAV | 10.00 % | 0.00 % |
N/A |
N/A | |
| MATH | Metalpha Technology Holdi.. | 0.00 % | 1.35 % |
N/A |
USD 0.04B |
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 8.04% | 57% | F | 70% | C- | ||
| Dividend Return | 0.13% | 20% | F | 2% | F | ||
| Total Return | 8.17% | 57% | F | 63% | D | ||
| Trailing 12 Months | |||||||
| Capital Gain | 18.78% | 100% | F | 81% | B- | ||
| Dividend Return | 0.16% | 17% | F | 2% | F | ||
| Total Return | 18.93% | 100% | F | 77% | C+ | ||
| Trailing 5 Years | |||||||
| Capital Gain | 14.82% | 33% | F | 56% | F | ||
| Dividend Return | 0.50% | 28% | F | 1% | F | ||
| Total Return | 15.31% | 29% | F | 45% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 3.12% | 33% | F | 52% | F | ||
| Dividend Return | 3.20% | 33% | F | 43% | F | ||
| Total Return | 0.08% | 26% | F | 2% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 32.97% | 19% | F | 30% | F | ||
| Risk Adjusted Return | 9.71% | 19% | F | 34% | F | ||
| Market Capitalization | 3.15B | N/A | N/A | N/A | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
